These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 3087274

  • 1. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Stamm JM, Hanson CW, Chu DT, Bailer R, Vojtko C, Fernandes PB.
    Antimicrob Agents Chemother; 1986 Feb; 29(2):193-200. PubMed ID: 3087274
    [Abstract] [Full Text] [Related]

  • 2. In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Fernandes PB, Chu DT, Bower RR, Jarvis KP, Ramer NR, Shipkowitz N.
    Antimicrob Agents Chemother; 1986 Feb; 29(2):201-8. PubMed ID: 3521473
    [Abstract] [Full Text] [Related]

  • 3. The comparative in-vitro activity of pefloxacin.
    King A, Phillips I.
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():1-10. PubMed ID: 2940213
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of A-56619 and A56620, two new aryl-fluoroquinolone antimicrobial agents.
    Smith BR, LeFrock JL, Donato JB, Joseph WS, Weber SJ.
    Antimicrob Agents Chemother; 1986 Feb; 29(2):355-8. PubMed ID: 3717937
    [Abstract] [Full Text] [Related]

  • 5. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.
    Fu KP, Neu HC.
    Antimicrob Agents Chemother; 1978 Mar; 13(3):358-67. PubMed ID: 122519
    [Abstract] [Full Text] [Related]

  • 6. In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
    Eliopoulos GM, Moellering AE, Reiszner E, Moellering RC.
    Antimicrob Agents Chemother; 1985 Oct; 28(4):514-20. PubMed ID: 3935046
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of T-3761, a new fluoroquinolone.
    Muratani T, Inoue M, Mitsuhashi S.
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2293-303. PubMed ID: 1332594
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
    Hosaka M, Yasue T, Fukuda H, Tomizawa H, Aoyama H, Hirai K.
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2108-17. PubMed ID: 1332587
    [Abstract] [Full Text] [Related]

  • 9. Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.
    Gargallo D, Moros M, Coll R, Esteve M, Parés J, Xicota MA, Guinea J.
    Antimicrob Agents Chemother; 1988 May; 32(5):636-41. PubMed ID: 3134844
    [Abstract] [Full Text] [Related]

  • 10. Activity of ciprofloxacin against resistant clinical isolates.
    Kelley SG, Bertram MA, Young LS.
    J Antimicrob Chemother; 1986 Mar; 17(3):281-6. PubMed ID: 2939048
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests.
    Barry AL, Jones RN, Thornsberry C, Ayers LW, Gavan TL, Gerlach EH.
    Eur J Clin Microbiol; 1986 Feb; 5(1):18-22. PubMed ID: 2938944
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620 compared to that of other antimicrobial agents.
    Hirschhorn L, Neu HC.
    Chemotherapy; 1987 Feb; 33(1):28-39. PubMed ID: 3549179
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.
    Gargallo-Viola D, Esteve M, Llovera S, Roca X, Guinea J.
    Antimicrob Agents Chemother; 1991 Mar; 35(3):442-7. PubMed ID: 2039195
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of the new 4-quinolone compound Ro 23-6240.
    Clarke AM, Zemcov SJ.
    Eur J Clin Microbiol; 1987 Apr; 6(2):161-4. PubMed ID: 3109895
    [Abstract] [Full Text] [Related]

  • 15. Lomefloxacin activity against 2,813 clinical isolates: a collaborative study at three medical centers in Brazil.
    Magalhaes M, Trabulsi LR, Montelli AC.
    Diagn Microbiol Infect Dis; 1989 Apr; 12(3 Suppl):35S-39S. PubMed ID: 2791496
    [Abstract] [Full Text] [Related]

  • 16. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A, Phillips I.
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of aryl fluoroquinolones, Abbott 56619 and Abbott 56620, compared to ciprofloxacin, norfloxacin and beta-lactams versus multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Meyer RD, Liu S.
    Chemotherapy; 1986 Nov; 32(5):425-30. PubMed ID: 3093154
    [Abstract] [Full Text] [Related]

  • 18. Activity of imipenem on aerobic bacteria.
    Acar JF, Goldstein FW, Kitzis MD, Gutmann L.
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():37-45. PubMed ID: 6421793
    [Abstract] [Full Text] [Related]

  • 19. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria.
    Wakebe H, Mitsuhashi S.
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2185-91. PubMed ID: 1332589
    [Abstract] [Full Text] [Related]

  • 20. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
    Jones RN, Barrett MS, Erwin ME, Briggs BM, Johnson DM.
    Diagn Microbiol Infect Dis; 1991 Oct; 14(4):319-30. PubMed ID: 1909615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.